Exponent(US:EXPO)2025-05-01 20:05Revenue Performance - Total revenues for Q1 2025 were approximately flat at $145.5 million, compared to $144.9 million in Q1 2024[5] - Exponent anticipates low-single digit revenue growth for the full fiscal year 2025 compared to fiscal year 2024[10] - The engineering and other scientific segment accounted for 84% of revenues before reimbursements, remaining flat year-over-year[8] - The environmental and health segment represented 16% of revenues before reimbursements, with a 2% increase driven by the chemicals industry[9] Income and Profitability - Net income decreased to $26.7 million, or $0.52 per diluted share, down from $30.1 million, or $0.59 per diluted share in Q1 2024[6] - EBITDA decreased to $37.5 million, representing 27.3% of net revenues, compared to $40.1 million, or 29.2% of net revenues in Q1 2024[7] - Exponent's operating income for Q1 2025 was $44.4 million, compared to $30.7 million in Q1 2024[22] - Net income for the quarter ended April 4, 2025, was $26,650 million, a decrease of 4.9% from $30,142 million in the same quarter of 2024[28] - EBITDA for the quarter was $37,538 million, down 6.4% from $40,121 million year-over-year[28] - EBITDAS for the quarter was $45,717 million, a decline of 3.7% compared to $47,461 million in the previous year[28] Expenses and Taxation - Income taxes increased to $11,110 million from $10,281 million, reflecting a rise of 8.1%[28] - Stock-based compensation rose to $8,179 million, up 11.4% from $7,340 million in the prior year[28] - Depreciation and amortization expenses increased to $2,492 million, compared to $2,324 million, marking a growth of 7.2%[28] - Interest income, net, was $(2,714) million, slightly higher than $(2,626) million in the previous year[28] - The consolidated tax rate for Q1 2025 was 29.4%, up from 25.4% in Q1 2024[6] Cash and Dividends - The company plans to maintain its quarterly cash dividend of $0.30, with $16.4 million paid in dividends during Q1 2025[7] - Exponent closed the quarter with $245.1 million in cash and cash equivalents[7] Operating Performance Measures - The company emphasizes that EBITDA and EBITDAS are useful measures of operating performance and cash flow, providing meaningful comparisons of past, present, and future results[29] - Management believes that non-GAAP measures like EBITDA and EBITDAS should be considered in addition to GAAP measures for a comprehensive view of financial performance[29] - The company continues to focus on enhancing operating performance despite the decline in net income and EBITDA metrics[29]